Skip to main content

Table 3 LSM at baseline and change at weeks 12 and 24

From: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

PRO assessment

UPA 15 mg

(n=303)

ABA IVa

(n=309)

Baseline

Mean ± SD

Difference at week 

12

LSM (95%CI)

Difference at week 

24

LSM (95%CI)

Baseline

Mean ± SD

Difference at week 

12

LSM (95%CI)

Difference at week

24

LSM (95%CI)

PtGA

66.8 ± 19.9

− 33.9*

(− 37.1, − 30.6)

− 38.7

(− 42.1, − 35.3)

69.6 ± 20.8

− 28.4

(− 31.5, − 25.2)

− 36.9

(− 40.2, − 33.5)

Pain (VAS)

68.0 ± 20.2

− 35.3*

(− 38.5, − 32.0)

− 41.5

(− 44.8, − 38.2)

70.8 ± 19.5

− 30.0

(− 33.2, − 26.8)

− 37.7

(− 41.0, − 34.4)

HAQ-DI

1.7 ± 0.6

− 0.65*

(− 0.72, − 0.57)

− 0.79*

(− 0.87, − 0.70)

1.7 ± 0.6

− 0.48

(− 0.55, − 0.40)

− 0.66

(− 0.74, − 0.58)

FACIT-F

25.3 ± 11.2

9.6 (8.3, 10.9)

10.7 (9.4, 12.1)

25.6 ± 11.3

8.4 (7.1, 9.6)

10.3 (9.0, 11.7)

Morning stiffness

 Severityb

6.4 ± 2.3

− 3.3*

(− 3.6, − 3.0)

− 3.9*

(− 4.2, − 3.6)

6.5 ± 2.4

− 2.8

(− 3.1, − 2.5)

− 3.5

(− 3.8, − 3.2)

 Durationc

185.5 ± 280.5

− 74.4

(− 110.1, − 38.6)

− 97.1

(− 134.1, − 60.1)

207.2 ± 311.5

− 70.8

(− 105.9, − 35.8)

− 92.8

(− 129.5, − 56.0)

EQ-5D-5L index score

0.5 ± 0.3

0.26* (0.23, 0.28)

0.28 (0.26, 0.30)

0.5 ± 0.3

0.21 (0.19, 0.24)

0.25 (0.23, 0.28)

WPAI domains

 Absenteeism

22.4 ± 30.8

− 11.0

(− 16.5, − 5.4)

− 15.8

(− 21.2, − 10.4)

21.6 ± 30.7

− 13.0

(− 18.8, − 7.1)

− 10.5

(− 16.3, − 4.6)

 Presenteeism

54.3 ± 23.3

− 26.0*

(− 32.4, − 19.6)

− 26.0

(− 32.6, − 19.4)

52.7 ± 27.3

− 17.5

(− 24.2, − 10.8)

− 23.0

(− 30.3, − 15.7)

 Overall work impairment

62.2 ± 26.8

− 25.7

(− 32.8, − 18.5)

− 29.8

(− 37.0, − 22.5)

60.9 ± 30.0

− 22.1

(− 29.7, − 14.6)

− 25.5

(− 33.4, − 17.7)

 Activity impairment

64.4 ± 22.0

− 26.8*

(− 30.1, − 23.5)

− 31.5*

(− 35.0, − 28.0)

67.2 ± 22.5

− 21.0

(− 24.2, − 17.7)

− 25.8

(− 29.3, − 22.3)

SF-36 composite scores

 SF-36 PCS

31.2 ± 7.4

9.6* (8.6, 10.7)

11.0* (9.8, 12.1)

31.3 ± 6.8

7.0 (6.0, 8.1)

9.4 (8.3, 10.5)

 SF-36 MCS

43.7 ± 11.6

5.6 (4.5, 6.8)

6.4 (5.2, 7.7)

42.8 ± 12.1

5.8 (4.7, 7.0)

6.4 (5.2, 7.6)

SF-36 domain scores

 SF-36 PF

30.7 ± 8.4

8.6* (7.5, 9.8)

10.1 (8.9, 11.3)

30.5 ± 8.3

5.9 (4.8, 7.1)

8.7 (7.5, 9.9)

 SF-36 RP

33.4 ± 7.6

7.9 (6.9, 9.0)

9.6 (8.4, 10.7)

32.8 ± 7.7

7.0 (5.9, 7.9)

8.5 (7.4, 9.7)

 SF-36 BP

32.9 ± 6.5

12.2* (11.1, 13.4)

13.4* (12.3, 14.6)

32.5 ± 6.6

9.8 (8.7, 10.9)

11.7 (10.6, 12.9)

 SF-36 GH

37.3 ± 8.9

6.7* (5.5, 7.9)

7.1 (6.0, 8.3)

37.3 ± 7.9

5.0 (3.8, 6.1)

6.4 (5.2, 7.5)

 SF-36 VT

40.2 ± 9.6

8.6 (7.4, 9.9)

10.0 (8.6, 11.3)

40.3 ± 9.3

7.7 (6.4, 8.9)

9.3 (8.0, 10.7)

 SF-36 SF

37.7 ± 10.5

7.8 (6.6, 8.9)

9.3 (8.1, 10.5)

37.4 ± 10.6

6.6 (5.5, 7.8)

8.0 (6.7, 9.2)

 SF-36 RE

39.2 ± 11.3

5.5 (4.4, 6.7)

6.8 (5.6, 8.1)

37.7 ± 11.9

5.5 (4.3, 6.7)

6.5 (5.3, 7.8)

 SF-36 MH

41.0 ± 11.1

6.9 (5.7, 8.1)

7.3 (6.1, 8.6)

40.2 ± 11.4

6.3 (5.1, 7.5)

7.1 (5.9, 8.4)

  1. aABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1000 mg). bAssessed on a numeric scale of 1–10, with 10 being the worst level. cDuration in minutes. ABA abatacept, AM morning, BP bodily pain, EQ-5D-5L (index score) EQ-5D 5-Level, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, GH general health, HAQ-DI Health Assessment Questionnaire Disability Index, IV intravenous, LSM least squares mean, MCS Mental Component Summary, MH mental health, PCS Physical Component Summary, PF physical functioning, PRO patient-reported outcome, PtGA Patient Global Assessment of Disease Activity, QD once daily, RE role emotional, RP role physical, SF social functioning, SF-36 36-Item Short Form Health Survey, UPA upadacitinib, VAS visual analog scale, VT vitality, WPAI Work Productivity and Activity Impairment. *P<0.05 for UPA vs ABA. P values represent statistical significance between groups